Implications of Abdominal Adipose Tissue Distribution on Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Chinese General Population Study

Chileka Chiyanika, BSc, PgD, MSc,1 Vincent Wai-Sun Wong, MBChB, MD, FRCP, FHKAM, FHKCP2,3, Grace Lai-Hung Wong, MBChB, MD, FRCP, FHKAM, FHKCP2,3, Henry Lik-Yuen Chan, MBChB, MD, FRCP, FHKCP, FHKAM2,3, Steve C. N. Hui, BSc, MSc, PhD4, David K. W. Yeung, BSc, MSc, PhD1,5 and Winnie C. W. Chu, MBChB, MD, FRCR, FHKAM1

INTRODUCTION: Visceral adipose tissue (VAT) has been found to play a critical role in the development of metabolic syndrome and nonalcoholic fatty liver disease (NAFLD) independent of generalized obesity.

METHODS: In this secondary study of prospectively acquired data, 625 participants underwent magnetic resonance spectroscopy and chemical shift fat–water separation MRI (2-point Dixon) of the liver and whole abdomen, respectively, in a 3 Tesla magnet. Whole abdominal VAT and subcutaneous adipose tissue (SAT) were extracted from the 2-point Dixon image series using an automated method. Clinical/anthropometric/blood biochemistry parameters were measured. Using region-specific body mass index, participants were classified into 3 paired subgroups (lean, overweight, and obese) and presence of NAFLD (liver fat content ≥ 5.5%).

RESULTS: All relevant clinical/anthropometric/blood biochemistry characteristics and liver enzymes were statistically significant between groups (P < 0.001). NAFLD was found in 12.1%, 43.8%, and 68.3% and metabolic syndrome in 51.1%, 61.9%, and 65% of the lean, overweight, and obese, respectively. Odds ratio for metabolic syndrome and NAFLD was increased by 2.73 (95% confidence interval [CI] 2.18–3.40) and 2.53 (95% CI 2.04–3.12), respectively, for 1SD increase in VAT volume while prevalence of metabolic syndrome was increased by 2.26 (95% CI 1.83–2.79) for 1SD increase in liver fat content (%). VAT/SAT ratio in the lean with fatty liver showed the highest ratio (0.54) among all the subgroups, without a significant difference between the lean and obese with NAFLD (P = 0.127).

DISCUSSION: Increased VAT volume/disproportional distribution of VAT/SAT may be vital drivers to the development of metabolic syndrome and NAFLD irrespective of body mass index category.

© 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology
NAFLD independent of generalized obesity (7). Although VAT is a principal cause of high prevalence of NAFLD globally and is strongly associated with metabolic syndrome (8), population studies on the connection among lean/overweight/obese populations with NAFLD especially those that used chemical shift–encoded MRI as an accurate quantitative measure of both liver fat and visceral fat are not numerous. Most studies either used ultrasound or computed tomography to determine NAFLD and VAT measured as either visceral fat area or volume with computed tomography or dual-energy x-ray absorptiometry.

In this study, we sought to evaluate the association of abdominal adipose distribution (VAT/subcutaneous adipose tissue [SAT]) with fatty liver infiltration and metabolic syndrome development in the lean, overweight, and obese adult populations using a chemical shift–encoded MRI method.

METHODS

Study participants

This study was a secondary analysis of a prospective trial by Wong et al. (9) reported previously, that determined the prevalence of NAFLD and advanced fibrosis in the general Chinese population in Hong Kong involving 922 participants, from which 625 are reported in this substudy. Our institutional review board approved the study, and written informed consent was obtained from all the participants. From May 2008 to September 2010, 625 participants who had undergone both liver magnetic resonance spectroscopy (MRS) and supplementary chemical shift encoding–based water–fat separation imaging (2-point Dixon) technique were enrolled in this substudy after excluding 297 of the initial 922 (Figure 1). The study included participants aged 18–70 years with an alcohol consumption limit of 30 g/d for men and 20 g/d for women. Exclusion criteria included any active malignancy, hepatitis B surface antigen positive or positive antibody against hepatitis C virus, being on medication known to affect liver fat, decompensated liver disease, and all known MRI contraindications.

Clinical assessment

During the medical clinic visit, medical history, drug history, alcohol intake, and smoking were recorded using a standardized questionnaire. The body weight, height, waist circumference, and systolic and diastolic blood pressures were measured and recorded accordingly. Body mass index (BMI) was used to categorize BMI status of the participants using the ethnic specific cutoff values (10): BMI < 23 kg/m², 23–24.9 kg/m², and ≥25 kg/m² for lean, overweight, and obese status, respectively. Blood tests (liver biochemistry, glucose, and lipids) were performed for participants after at least 8 hours of fasting.

The modified ethnic specific International Diabetes Federation criteria were used to define metabolic syndrome as any 3 of the following: central obesity (waist circumference ≥90 cm in men and ≥80 cm in women), triglycerides >1.7 mmol/L, high-density lipoprotein-cholesterol <1.03 mmol/L in men and <1.29 mmol/L in women, blood pressure ≥130/80 mm Hg and fasting plasma glucose ≥5.6 mmol/L, or on treatment for the above metabolic aberrations (11).

Magnetic resonance image acquisition and reconstruction

MRI was performed in all participants within 8 weeks from baseline using a 3.0 T scanner (Achieva; Philips Medical Systems, Best, the Netherlands). Chemical shift water–fat 2-point Dixon sequence was used to obtain fat-only, water-only, in-phase, and out-of-phase image series of the whole abdomen. VAT and SAT volumes were automatically extracted and quantified from the abdominal MRI series using an in-house method, developed using insight segmentation and registration toolkit (12). Briefly, this method is based on the application of K-means (K = 2) clustering and gradient-vector-field–driven deformable model algorithms.

Figure 1. Flow chart of the study population. BMI, body mass index; MRS, magnetic resonance spectroscopy; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue.
Proton MRS

During the same MRI scan, a single voxel PRESS sequence was performed using the body coil without water suppression to acquire a spectrum of intrahepatic triglycerides. A $20 \times 15 \times 40$-mm$^3$ voxel was placed in the right liver lobe, avoiding major vessels. Selecting short echo time and long repetition time,

| Table 1. Clinical and anthropometric characteristics of participants according to weight and fatty liver status |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Variable        | All participants, N = 625 | Lean without fatty liver, N = 326 | Lean with fatty liver, N = 45 | Overweight without fatty liver, N = 109 | Overweight with fatty liver, N = 85 | Obese without fatty liver, N = 19 | Obese with fatty liver, N = 41 |
| Age (y)         | 48 ± 10         | 47 ± 11         | 50 ± 10         | 49 ± 10         | 53 ± 8          | 45 ± 8          | 50 ± 9          | <0.001b |
| Men             | 49 ± 11         | 47 ± 13         | 50 ± 10         | 47 ± 12         | 53 ± 8          | 50 ± 2          | 48 ± 9          | 0.085 |
| Women           | 48 ± 10         | 47 ± 10         | 50 ± 9          | 50 ± 8          | 54 ± 9          | 44 ± 8          | 51 ± 9          | <0.001 |
| Male, n (%)     | 38              | 27              | 52              | 49              | 58.7            | 22.2            | 40.5            | 0.046 |
| Female, n (%)   | 62              | 73              | 48              | 51              | 41.3            | 77.2            | 59.5            |       |
| BMI (kg/m$^2$)  | 22.9 ± 3.5      | 20.5 ± 1.7      | 21.7 ± 1.3      | 24.9 ± 1.2      | 25.1 ± 1.2      | 30.2 ± 3.6      | 30.0 ± 3.2      | <0.001a |
| Systolic blood pressure (mm Hg) | 81.2 ± 9.9    | 75.1 ± 7.4      | 84.2 ± 7.3      | 85.6 ± 7.0      | 89.0 ± 5.0      | 90.8 ± 9.5      | 95.2 ± 9.6      | <0.001a |
| Diastolic blood pressure (mm Hg) | 86.1 ± 7.9    | 79.7 ± 5.1      | 86.2 ± 6.6      | 88.7 ± 5.9      | 89.4 ± 4.4      | 96.0 ± 6.7      | 98.9 ± 8.4      | <0.001 |
| Liver fat content (%) | 4.75 ± 6.1    | 1.51 ± 1.1      | 11.6 ± 7.6      | 2.53 ± 1.4      | 11.5 ± 6.2      | 2.50 ± 1.4      | 13.91 ± 8.1     | <0.001a |
| VAT volume (L)  | 1.92 ± 1.43     | 1.31 ± 0.89     | 2.72 ± 1.84     | 2.21 ± 1.35     | 2.77 ± 1.57     | 2.26 ± 1.24     | 2.93 ± 1.75     | <0.001a |
| SAT volume (L)  | 2.48 ± 1.74     | 1.60 ± 1.12     | 3.13 ± 1.98     | 2.61 ± 1.62     | 3.08 ± 1.82     | 2.43 ± 1.92     | 3.51 ± 2.05     | <0.001 |
| VAT/SAT ratio   | 0.50 ± 0.28     | 0.43 ± 0.23     | 0.69 ± 0.35     | 0.46 ± 0.23     | 0.62 ± 0.29     | 0.39 ± 0.23     | 0.55 ± 0.33     | <0.001 |
| Metabolic syndrome, n (%) | 32.4            | 12              | 51.1            | 47.7            | 61.9            | 50              | 65              | <0.001a |
| Hypertension, n (%) | 50.6            | 40              | 51.1            | 56.5            | 74.1            | 47.4            | 70.7            | <0.001a |

BMI, body mass index; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue.

*a*Indicates at least 1 group of significant differences using the Welch test, and post hoc analysis was performed.

*b*Indicates at least 1 group of significant differences using ANOVA, and post hoc analysis was performed.
respectively, minimized T2 and T1 effects. A noncommercially available jMRUI software package (13) was used for spectral analysis. Liver fat fraction was obtained from the main methylene signal of fat and calculated using equation (1).

$$\text{FF}(\%) = \frac{\text{signal intensity of fat}}{\text{sum of signal intensity of fat and water}} \times 100 \quad (1)$$

**Statistical analysis**

Normally distributed data were expressed as mean ± SD, unless stated otherwise. Analysis of variance (ANOVA) and Welch ANOVA were used as necessary. Post hoc analyses were performed by using Scheffe or Dunnett T3 methods accordingly. The Mann-Whitney U test was used for testing differences between 2 groups. Linear trends were tested using the $t^2$ test. Associations were tested using Pearson correlation coefficients. Multiple linear and binary logistic regression analyses with correction for multiple comparisons were used to evaluate causation relationships. All tests were 2-sided and $P$ values <0.05 were considered statistically significant. Statistical analyses were performed with SPSS software, version 25.0 (IBM, Chicago, IL).

**RESULTS**

**Participant characteristics**

Six hundred twenty-five participants (38% men, 62% women, 48 ± 10 years; age range 19–70 years, BMI 22.9 ± 3.5 kg/m², BMI range 15.8–42.7 kg/m²) were analyzed. Men had a higher VAT volume than women ($P < 0.001$) while women had higher SAT volume than men ($P < 0.001$). VAT volume, liver fat content, and prevalence of metabolic syndrome increased exponentially with age ($P < 0.001$). The prevalence of metabolic syndrome and fatty liver disease in men was 41.9% and 37.4%, respectively, while in women, it was 26.5% and 21%, respectively, with a significant difference between them ($P < 0.001$).

The study cohort was classified into 3 pairwise subgroups according to their BMI and presence of fatty liver as follows: group 1a—lean without fatty liver ($n = 326$); group 1b—lean with fatty liver ($n = 45$ or 12.1%); group 2a—overweight without fatty liver ($n = 109$); group 2b—overweight with fatty liver ($n = 85$ or 43.8%); group 3a—obese without fatty liver ($n = 19$); and group 3b—obese with fatty liver ($n = 41$ or 68.3%).

**Clinical, anthropometric, and blood biochemistry characteristics**

All clinical, anthropometric, and blood biochemistry characteristics were significantly different between groups ($P < 0.001$) except for aspartate aminotransferase ($P < 0.261$), total bilirubin ($P < 0.651$), and albumin ($P < 0.786$) (Tables 1 and 2). In addition, there were significant differences in biochemistry and liver enzymes between sex ($P < 0.001$) except for cholesterol ($P = 0.469$), low-density lipoprotein-cholesterol ($P = 0.106$), and HbA1c ($P = 0.064$).

**Adipose tissue and metabolic syndrome**

Metabolic syndrome was diagnosed in 202 or 32.4% of the entire study cohort with a significant difference between those with and without fatty liver disease ($P < 0.001$). The distribution of metabolic syndrome in those with fatty liver was 51.1%, 61.9%, and 65% in the lean, overweight, and obese, respectively. The incidence of metabolic syndrome showed an increasing linear trend with an increase in VAT volume ($P < 0.001$), but a higher prevalence was observed in the fatty liver subgroups.

Interestingly, post hoc analysis showed no significant difference in the prevalence of metabolic syndrome between the lean with fatty liver subgroup and in all overweight/obese subgroups ($P = 1.000, 0.994, 1.000, and 0.963$), indicating that lean participants with fatty liver were as metabolically unhealthy as the overweight/obese participants with fatty liver.

Table 3 summarizes the pairwise subgroup comparisons in those with and without metabolic syndrome. The results indicated that VAT volume in the lean and obese groups added a risk to the development of metabolic syndrome. Notably, a trend of increased VAT volume was observed in the overweight subgroups with metabolic syndrome except that this difference was not statistically significant ($P > 0.05$). Meanwhile, comparison by sex showed that VAT, SAT, VAT/SAT ratio, and liver fat content in those with and without metabolic syndrome were significantly different between them ($P < 0.001$).

Multiple linear regression analysis showed age ($P < 0.001$), waist circumference ($P = 0.003$), VAT volume ($P < 0.001$), and VAT/SAT ratio ($P = 0.012$) as predictors of metabolic syndrome after controlling for sex, SAT, waist-to-hip ratio, BMI and liver fat content ($R^2 = 0.352$). The odds ratio (OR) of metabolic syndrome was increased by 2.73 (95% confidence interval [CI] 2.18–3.40) for 1SD increase in VAT volume while it was increased by 2.26 (95% CI 1.83–2.79) for 1SD increase in liver fat content (%). Moreover, VAT, SAT, and VAT/SAT ratio all showed significant association with metabolic syndrome ($P < 0.001$) (Table 4).

**Adipose tissue and NAFLD**

In the entire cohort, VAT volume, SAT volume, and VAT/SAT ratio were significantly higher in those with fatty liver disease than in those without ($P < 0.001, 0.004$, and $<0.001$, respectively). Intriguingly, post hoc analyses showed that VAT volume was not significantly different between 1b and 2a/b ($P = 1.000, 0.683$), 1b and 3a/b ($P = 1.000, 0.966$), suggesting that VAT volume in the lean with NAFLD was as high and similar to VAT volume in both the overweight and obese participants regardless of the presence of NAFLD.

SAT volume was not significantly different between the lean subgroups ($P = 1.000$), overweight subgroups ($P = 0.398$), and obese subgroups ($P = 0.119$), indicating that SAT volumes in those with and without NAFLD in each BMI category were similar. VAT/SAT ratio was not significantly different between 1b and 2b/3a and b ($P = 1.000, 0.065, 0.127$). VAT/SAT ratio in the lean with fatty liver subgroup showed the highest ratio (0.54) among all the subgroups, suggesting a disproportional distribution of fat in this subgroup, with an increased fat deposition in the visceral as opposed to the subcutaneous region.

Liver fat content was not significantly different between subgroups 1a and 3a, 1b and 2b, 1b and 3b, 2a and 3a, and 2b and 3b ($P = 0.105, 1.000, 0.861, 1.000, and 0.738$), suggesting that there could be another mechanism responsible for ectopic fat infiltration in the liver other than general and central obesity. The incidence of fatty liver disease showed an increasing linear trend with an increase in VAT volume ($P < 0.001$). The OR of fatty liver was increased by 2.53-fold (95% CI 2.04–3.12) for 1SD increase in VAT volume.

Binary logistic regression analysis showed male gender ($P < 0.001$), BMI ($P < 0.001$), waist circumference ($P < 0.001$), alanine
in our cohort seems to be higher, and this discrepancy could be
prevalence of metabolic syndrome in the lean population with
fatty liver in the lean population ranges from 7% to 20% (16,17)
65% in the lean, overweight, and obese, respectively.

American College of Gastroenterology

DISCUSSION

VAT is associated with metabolic syndrome (14) and fatty liver
disease (15). In this present population substudy involving
asymptomatic general adult Hong Kong Chinese population,
MRS and fat–water separation MRI methods were used. Preva-
ience of NAFLD was 12.1%, 43.8%, and 68.3% in the lean, over-
weight, and obese, respectively, while the prevalence of metabolic
syndrome in participants with fatty liver was 51.1%, 61.9%, and
65% in the lean, overweight, and obese, respectively.

In agreement with previous studies, the global occurrence of
fatty liver in the lean population ranges from 7% to 20% (16,17)
and 50%–90% in the obese (18–20). Previously reported global
prevalence of metabolic syndrome in the lean population with
fatty liver disease ranges from 14% to 37.8% (16) and 46.6% in
overweight/obese Chinese (21). Metabolic syndrome prevalence
in our cohort seems to be higher, and this discrepancy could be
attributed to different methods used to diagnose fatty liver dis-
ease, criteria to diagnose metabolic syndrome and the varying/

Am. Coll. Gastroenterol.
Clinical and Transl. Gastroenterol.

Table 2. Blood biochemistry characteristics of the study population by weight and fatty liver status

| Variables               | All participants, N = 629 | Lean/no fatty liver, N = 323 | Lean/with fatty liver, N = 48 | Overweight/no fatty liver, N = 102 | Overweight/with fatty liver, N = 92 | Obese/no fatty liver, N = 18 | Obese/with fatty liver, N = 42 | P value                        |
|-------------------------|---------------------------|-----------------------------|-----------------------------|-----------------------------------|------------------------------------|-------------------------------|-------------------------------|--------------------------------|
| ALT (IU/L)              | 25.6 ± 16.5               | 21.0 ± 10.7                 | 33.2 ± 17.1                 | 26.3 ± 22.8                       | 32.4 ± 15.3                        | 22.6 ± 9.4                     | 37.4 ± 24.2                   | <0.001a                        |
| AST (IU/L)              | 21.5 ± 16.5               | 21.1 ± 17.3                 | 33.8 ± 13.1                 | 20.1 ± 5.9                        | 23.3 ± 7.9                         | 18.4 ± 4.6                     | 24.0 ± 10.0                   | 0.261                          |
| ALP (IU/L)              | 64.3 ± 18.7               | 61.3 ± 19.8                 | 69.2 ± 16.8                 | 64.7 ± 16.8                       | 72.4 ± 17.3                        | 58.3 ± 11.2                    | 66.1 ± 15.7                   | <0.001b                        |
| Total bilirubin (mmol/L)| 13.1 ± 5.7                | 13.2 ± 5.9                  | 12.5 ± 4.7                  | 12.6 ± 4.9                        | 13.0 ± 6.3                         | 14.9 ± 8.2                     | 13.0 ± 4.7                    | 0.651                          |
| HbA1c (%)               | 5.4 ± 0.7                 | 5.3 ± 0.4                   | 5.8 ± 1.2                   | 5.5 ± 0.5                         | 5.6 ± 0.7                          | 5.2 ± 0.4                      | 5.9 ± 1.1                     | <0.001a                        |
| Hemoglobin (g/dL)       | 13.8 ± 1.5                | 13.5 ± 1.4                  | 14.2 ± 1.2                  | 13.9 ± 1.5                        | 14.4 ± 1.7                         | 13.3 ± 1.1                     | 14.4 ± 1.4                    | <0.001b                        |
| Ferritin                | 467.9 ± 482.1             | 355.1 ± 392.4               | 611.6 ± 466.9               | 455.1 ± 414.3                     | 740.8 ± 609.8                      | 298.9 ± 361.9                  | 683.8 ± 672.2                 | <0.001a                        |
| AST/ALT ratio           | 0.97 ± 0.74               | 1.12 ± 0.97                 | 0.77 ± 0.29                 | 0.91 ± 0.32                       | 0.79 ± 0.26                        | 0.86 ± 0.19                    | 0.72 ± 0.20                   | <0.001b                        |
| Fasting glucose (IU/L)  | 5.12 ± 1.02               | 4.86 ± 0.44                 | 5.67 ± 1.64                 | 5.25 ± 0.77                       | 5.36 ± 0.87                        | 4.96 ± 0.53                    | 5.70 ± 1.59                   | <0.001a                        |
| Albumin (mmol/L)        | 45.1 ± 2.7                | 45.1 ± 2.9                  | 45.2 ± 3.0                  | 44.8 ± 2.21                       | 43.4 ± 2.3                         | 44.7 ± 2.8                     | 45.1 ± 2.2                    | 0.786                          |
| Total cholesterol (mmol/L)| 5.2 ± 1.0                | 5.08 ± 0.92                 | 5.38 ± 1.16                 | 5.24 ± 1.13                       | 5.48 ± 1.1                         | 5.53 ± 1.5                     | 5.17 ± 0.81                   | 0.012b                         |
| HDL-cholesterol (mmol/L)| 1.6 ± 0.4                 | 1.71 ± 0.40                 | 1.36 ± 0.27                 | 1.48 ± 0.36                       | 1.28 ± 0.31                        | 1.56 ± 0.4                     | 1.28 ± 0.24                   | <0.001a                        |
| LDL-cholesterol (mmol/L)| 3.1 ± 0.9                 | 2.92 ± 0.81                 | 3.11 ± 1.05                 | 3.13 ± 0.88                       | 3.28 ± 0.91                        | 3.39 ± 1.5                     | 3.12 ± 0.67                   | 0.004a                         |
| Triglycerides (mmol/L)  | 1.4 ± 1.3                 | 1.00 ± 0.60                 | 2.17 ± 1.66                 | 1.37 ± 1.01                       | 2.24 ± 2.52                        | 1.22 ± 1.06                    | 1.68 ± 1.06                   | <0.001a                        |

ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

*aIndicates at least 1 group of significant differences using the Welch test, and post hoc analysis was performed.

*bIndicates at least 1 group of significant differences using ANOVA, and post hoc analysis was performed.

It has been shown that the mean VAT volumes are significantly higher in the fatty liver subgroups than in those without. In fact, the VAT/SAT ratios are significantly higher in all fatty liver subgroups, with the lean with fatty liver subgroup showing the highest VAT/SAT ratio among them, suggesting that there is a limited subcutaneous mass relative to expanding visceral mass (an indication of the thin on the outside, fat on the inside phenotype) in this subgroup. These outcomes are in agreement with the hypothesis that increased VAT mass (representing adipocytes hyperplasia or hypertrophy) plays a significant mediatory role in the development of fatty liver disease either by direct delivery of free fat acids into the liver through the portal circulation or as a secondary effect from the dysfunctional adipocytes that produce more inflammatory adipokines and cytokines (interleukin 6 and tumor necrosis factor—alpha) (22), with dysfunctional adipocytes in particular, affecting the lean.

Despite VAT volume not being an independent predictor of fatty liver disease in this current study, increased VAT volume has nearly 3-fold greater risk of the development of fatty liver disease in our cohort. Previous Australian and Korean cohorts showed VAT volume/area had an OR 2.21 (per 1SD), 95% CI 1.1–4.2 (23) and OR 2.21 (per 1SD), 95% CI 1.25–3.89 (24), respectively, for the development of fatty liver disease.

One of the interesting and reassuring findings from the current study is that BMI and waist circumference (among others) are independent predictors of fatty liver disease in agreement with previous studies (25,26). In fact, Mansour et al. (27) further found that waist circumference was independently associated with liver

ethnic specific BMI cutoff values to categorize BMI status. The BMI cutoff in the Asian population is 2–5 BMI units lower than the international classification (10).

Table 2. Blood biochemistry characteristics of the study population by weight and fatty liver status

amino transferase (P = 0.030), total cholesterol (P = 0.045), high-
density lipoprotein-cholesterol (P = 0.001), and low-density
lipoprotein-cholesterol (P = 0.035) as independent predictors of
fatty liver after controlling for age, waist to hip ratio, VAT, SAT,
VAT/SAT ratio, triglycerides, ferritin, hemoglobin, aspartate
aminotransferase, alkaline phosphatase, and hypertension (R² =
0.538). Moreover, VAT, SAT, and VAT/SAT ratio all showed
significant association with fatty liver disease (P < 0.001). Liver
fat content also showed a significant association with metabolic
syndrome (P < 0.001) (Table 4).
fibrosis with OR 1.15, 95% CI 1.05–1.25. These tools are relatively inexpensive, simple to use, and appear to be sensitive and reliable markers in predicting fatty liver disease and its progression. However, in a more scientific point of view, waist circumference although more or less reflecting the amount of abdominal adipose tissue, it does not discriminate between VAT and SAT. Similarly, BMI does not differentiate between fat and muscle mass. In fact, as opposed to the causal role VAT volume seems to play in the development of fatty liver disease, SAT seems to have a protective effect as can be seen in the reduced prevalence of fatty liver disease in the females who have significantly increased SAT volume compared to males. Of course, we are not oblivious to the fact that this outcome could in part be explained by sex differences and related physiology. In support with this assertion, Kim et al. (28) concluded that increased SAT volume was associated with regression or decreased risk of fatty liver disease. This renders the use of waist circumference and BMI unreliable methods to infer the presence of fatty liver disease.

The incidence of metabolic syndrome is higher in the fatty liver subgroups and increases exponentially with increase in VAT volume in all groups. Post hoc analysis shows that the incidence of metabolic syndrome is not statistically different between the lean with fatty liver disease subgroup and the overweight/obese subgroups. Interestingly, VAT volume in all paired subgroups with metabolic syndrome is higher than in those without. In agreement with previous studies (29–31), metabolic syndrome has a significant linear relationship with VAT volume. Moreover, VAT volume, waist circumference, and VAT/SAT ratio are independent predictors of metabolic syndrome. In agreement with our findings, Bi et al. (32) and Nakao et al. (33) showed that VAT area was an independent predictor of metabolic syndrome.

In addition, the odds of metabolic syndrome are shown to increase by nearly 3-fold greater for 1SD increase in VAT volume. Post hoc analysis shows the incidence of metabolic syndrome is not statistically different between the lean with fatty liver disease subgroup and the overweight/obese subgroups. Interestingly, VAT volume in all paired subgroups with metabolic syndrome is higher than in those without. In agreement with previous studies (29–31), metabolic syndrome has a significant linear relationship with VAT volume. Moreover, VAT volume, waist circumference, and VAT/SAT ratio are independent predictors of metabolic syndrome. In agreement with our findings, Bi et al. (32) and Nakao et al. (33) showed that VAT area was an independent predictor of metabolic syndrome.
metabolic syndrome per 1SD of VAT area was 1.50 (95% CI 1.29–1.74). These results seem to support the hypothesis that increased VAT mass may have a causal effect in the development of metabolic syndrome.

Concerning the link between fatty liver and metabolic syndrome, we have shown that metabolic syndrome increases by 2.26-fold for 1SD increase in liver fat content. These findings are in concordance with Faria et al. study (29), which showed fatty liver infiltration had a 5.3-fold risk of metabolic syndrome. The prevalence of metabolic syndrome is significantly higher in the fatty liver disease subgroups than in those without. Similarly, fasting glucose/triglycerides (components of metabolic syndrome) are overly produced in NAFLD (35), a finding observed in our study. These outcomes demonstrate that fatty liver infiltration maybe a cause and consequence of a worsening metabolic condition regardless of the BMI category.

This study is not without limitations. Insulin resistance was not assessed despite its close association with VAT and NAFLD. There was a time gap of around 8 weeks between MRI/MRS and blood biochemistry/lipid profile/glucose tests, of which the metabolic profile could have changed. However, given that this was a study in asymptomatic population, the significance of time lapse is probably minimal and would be unlikely to affect the major observations in this study. Two-point Dixon technique and MRS were used as opposed to multiecho chemical shift–encoded MRI method, as the former was the available method at a time the main study was conducted. Finally, our study participants were Chinese with a relatively small sample size and using region-specific BMI cutoff; thus, caution must be taken in the generalizability of these results.

In conclusion, increased VAT volume (representing adipocytes hypertrophy or hyperplasia) and a disproportional distribution of VAT/SAT may be vital drivers to the development of metabolic syndrome and NAFLD irrespective of BMI category. Further studies on adipose tissue-liver cross-talk would be useful to understand the mechanism why some participants within the same BMI develop fatty liver disease and metabolic syndrome while others are spared despite having a comparable VAT volume. To date, multiecho chemical shift–encoded MRI technique can concurrently assess liver fat and adipose tissue while the application of segmentation program can readily calculate VAT and SAT volumes. These technical advances might shed light to personalized medicine assessment for understanding why some lean individuals over accumulate visceral abdominal fat while at the same time some obese individuals seem not to over accumulate visceral abdominal fat.

OUTCOMES

| Study Highlights |
|------------------|
| **WHAT IS KNOWN** |
| ✓ Nonalcoholic fatty liver disease (NAFLD) and metabolic syndrome are common manifestation of obesity. |
| ✓ Adipose tissue especially visceral adipose tissue (VAT) is a highly metabolic ectopic fat depot. |
| ✓ Chemical shift endoding (CSE) MRI is an established method to quantify fat in the human body. |
| **WHAT IS NEW HERE** |
| ✓ The OR for metabolic syndrome and NAFLD increased by 2.73 and 2.53, respectively, for 1SD increase in VAT volume. |
| ✓ There was no difference in VAT volume and VAT/SAT ratio between the lean with and obese with NAFLD, suggesting a “thin on the outside, fat on the inside phenotype” in the lean participants with NAFLD who also were as metabolically unhealthy as the overweight/obese participants with fatty liver. |
| ✓ The incidence of both metabolic syndrome and NAFLD increased linearly with an increase in VAT volume. |

**TRANSLATIONAL IMPACT**

✓ CSE MRI can accurately quantify liver fat and adipose tissue without the need for extra hardware while segmentation software programs can automatically quantify VAT and SAT volumes.
✓ These technical advances might shed light to personalized medicine assessment for understanding why some lean individuals over accumulate visceral abdominal fat while at the same time, some obese individuals seem not to over accumulate visceral abdominal fat.

**ACKNOWLEDGEMENTS**

We thank the following people for helping with data collection: Andrew Hayward, Catherine Hayward, Mandy Law, Mia Li, and April Wong. The authors thank all the participants who participated in the study.

**REFERENCES**

1. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell 2001;104:531–43.
2. Azzu V, Vacca M, Virtue S, et al. Adipose tissue-liver cross-talk in the control of whole-body metabolism: Implications in non-alcoholic fatty liver disease. Gastroenterology 2020;158:1899–912.
3. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15:11.
4. Wong VW, Adams LA, de Ledinghen V, et al. Noninvasive biomarkers in NAFLD and NASH-current progress and future promise. Nat Rev Gastroenterol Hepatol 2018;15:461–78.
5. Li L, Liu D, Yan H, et al. Obesity is an independent risk factor for non-alcoholic fatty liver disease: Evidence from a meta-analysis of 21 cohort studies. Obes Rev 2016;17:510–9.
6. Vernon G, Baranova A, Younossi Z. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274–85.
9. Wong VW, Chu WC, Wong GL, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: A population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012;61:409–15.

10. Fan J, Kim S, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol 2017;67:862–73.

11. Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57:1441–7.

12. Wang D, Shi L, Chu WC, et al. Fully automatic and nonparametric quantification of adipose tissue in fat-water separation MR imaging. Med Biol Eng Comput 2015;53:1247–54.

13. Stefan D, Di Cesare F, Andrasescu A, et al. Quantitation of magnetic resonance spectroscopy signals: The jMRUI software package. Meas Sci Technol 2009;20:104035.

14. Kure T, Mawatari S, Imamura Y, et al. Nonalcoholic fatty liver disease is associated with both subcutaneous and visceral adiposity: A cross-sectional study. Medicine (Baltimore) 2019;98:e17879.

15. Yu A, Duan-Mu Y, Zhang Y, et al. Correlation between non-alcoholic fatty liver disease and visceral adipose tissue in non-obese Chinese adults: A CT evaluation. Korean J Radiol 2018;19:223–9.

16. Albhaisi S, Chowdhury A, Sanyal AJ. Nonalcoholic fatty liver disease in non-obese patients: A population study. Medicine (Baltimore) 2019;98:e17879.

17. Shi Y, Wang Q, Sun Y, et al. The prevalence of lean/nonobese nonalcoholic fatty liver disease: A systematic review and meta-analysis. J Clin Gastroenterol 2020;54:378–387.

18. Sadek R, Wassef A, Mikhalj J, et al. Prevalence of non-alcoholic fatty liver disease in an obese population: Expected versus actual correlation. Surg Obes Relat Dis 2016;12:S203.

19. Divella R, Mazzocca A, Daniele A, et al. Obesity, nonalcoholic fatty liver disease and adipokines network in promotion of cancer. Int J Biol Sci 2019;15:610.

20. Wei JL, Leung JC, Loong TC, et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: A population study using proton-magnetic resonance spectroscopy. Am J Gastroenterol 2015;110:1306–14.

21. Feng RN, Du SS, Wang C, et al. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. World J Gastroenterol 2014;20:17932–40.

22. Snel M, Jonker JT, Schoones J, et al. Ectopic fat and insulin resistance: Pathophysiology and effect of diet and lifestyle interventions. Int J Endocrinol 2012;2012:983184.

23. van der Poorten D, Milner K, Hui J, et al. Visceral fat: A key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008;48:449–57.

24. Yu SJ, Kim W, Kim D, et al. Visceral obesity predicts significant fibrosis in patients with nonalcoholic fatty liver disease. Medicine (Baltimore) 2015; 94:e2159.

25. Pasanta D, Tungiai M, Chancharunee S, et al. Body mass index and its effects on liver fat content in overweight and obese young adults by proton magnetic resonance spectroscopy technique. World J Hepatol 2018;10: 924–33.

26. Clemente AFG, Dal Molin Netto B, de Carvalho-Ferreira JP, et al. [Waist circumference as a marker for screening nonalcoholic fatty liver disease in obese adolescents]. Revista Paulista de Pediatria 2016;34:47–55. Portuguese.

27. Mansour A, Mohajeri-Tehrani MR, Samadi M, et al. Risk factors for non-alcoholic fatty liver disease-associated hepatic fibrosis in type 2 diabetes patients. Acta Diabetol 2019;56:1199–207.

28. Kim D, Chung GE, Kwak M, et al. Body fat distribution and risk of incident and regressed nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2016;14:132–8.e4.

29. Faria G, Gonçalves A, Cunha R, et al. Beyond central adiposity: Liver fat and visceral fat area are associated with metabolic syndrome in morbidly obese patients. Int J Surg 2015;14:75–9.

30. Lopes HF, Corrêa-Giannella ML, Consolim-Colombo FM, et al. Visceral adiposity syndrome. Diabetol Metab Syndr 2018;6:40.

31. Kwon H, Kim D, Kim JS. Body fat distribution and the risk of incident metabolic syndrome: A longitudinal cohort study. Scientific Rep 2017;7:1–8.

32. Bi X, Seibolt L, Shibao C, et al. DXA-measured visceral adipose tissue predicts impaired glucose tolerance and metabolic syndrome in obese Caucasian and African-American women. Eur J Clin Nutr 2015;69:329–36.

33. Nakao YM, Miyawaki T, Yasuno S, et al. Intra-abdominal fat area is a predictor for new onset of individual components of metabolic syndrome: MEtabolic syndRome and abdominaL ObesiTy (MERLOT study). Proc Jpn Acad Ser B Phys Biol Sci 2012;88:454–61.

34. Fox C, Massaro J, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: Association with metabolic risk factors in the Framingham Heart Study. Circulation 2007;116:39–48.

35. Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2014;2:901–10.

Open Access This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.